Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00060203 · ClinicalTrials.gov registry record · Phase 1
Brostallicin in Treating Patients With Recurrent or Refractory Multiple Myeloma
A Phase 1 study, sponsored by Case Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT00060203: Completed Phase 1 study, sponsored by Case Comprehensive Cancer Center.
NCT00060203 is a Phase 1 study that has completed, run by Case Comprehensive Cancer Center. The registered enrollment target is 3 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00060203, a Phase 1 study, has completed, sponsored by Case Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy such as brostallicin use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I/II trial to study the effectiveness of brostallicin in treating patients who have recurrent or refractory multiple myeloma.
Primary Outcome
• Determine the objective tumor response rate (confirmed complete response and confirmed partial response) of brostallicin in patients with recurrent or refractory multiple myeloma
Interventions
- DRUG brostallicin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2002-12 |
| Est. Completion | 2004-04 |
| Phase | Phase 1 |
What the finished NCT00060203 record still lists
NCT00060203 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 1 intervention - of which brostallicin is the first listed.
NCT00060203 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00060203 about?
NCT00060203 is a clinical study titled "Brostallicin in Treating Patients With Recurrent or Refractory Multiple Myeloma". RATIONALE: Drugs used in chemotherapy such as brostallicin use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I/II trial to study the effectiveness of brostallicin in treating patients who have recurrent or refractory multiple myeloma.
What is the current status of trial NCT00060203?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2002-12. Estimated completion is 2004-04.
What interventions are being tested in trial NCT00060203?
The interventions under investigation include: brostallicin (DRUG).
Who is sponsoring clinical trial NCT00060203?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00060203's enrollment target sits among peer trials
3 1999th of 2000 higher than 1 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia